What is Drug re-positioning (DR)?

Drug re-positioning (DR) is a strategy to discover the new pharmacological effects of drugs sufficiently approved in terms of safety and pharmacokinetics in humans and to develop therapeutic agents for other diseases.

Advantages of drug re-positioning research

The following are major advantages of DR in pharmaceutical development:

  • 確実性
  • 低コスト性
  • 有効性

Characteristics of our DR

We have grown as a leading company in DR since focusing on its importance first in Japan.

Pharmaceutical drug screening with approved drug library

Using our own library targeted for compounds from drugs approved in Japan, we have performed various screenings to advance DR (including drugs for COPD, dry eye or functional dyspepsia). We also offer our library to partners for free and work together for DR promotion.

New drug development using approved drugs as lead compounds

To enhance the pharmacological effect of an approved drug from screening or obtain a substance patent, we have created a new substance by synthesizing derivatives with the approved drug as a lead compound (for example, LT-3001, LT-3002).

Rescue of drugs discontinued from development through DR

Many pharmaceutical companies have compounds discontinued from clinical development (shelved drugs) because of the lack of a pharmacological effect in spite of confirmation of clinical safety. Successful discovery of a pharmacological effect with DR development of a therapeutic agent for other diseases will bring great advantages to these companies. Our business includes DR of these compounds commissioned by major companies.

Examples of previous cases

  • 1. Development of a therapeutic agent for COPD with the approved-drug library
  • 2. Development of a therapeutic agent for dry eye with the approved-drug library
  • 3. Development of a therapeutic agent for functional dyspepsia with the approved-drug library
  • 4. Development of an anti-inflammatory drug with fewer side effects using DR
  • 5. Commissioned project for additional indication
  • 6. Collaborative research with universities and other companies using the approved-drug library

Flow of drug development by DR

By DR strategy, we can develop safe drugs,
rapidly, economically and certainly.